Clinical Implications of the T790M Mutation in Disease Characteristics and Treatment Response in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small-Cell Lung Cancer (NSCLC)

Our study confirms that tumors expressing T790M have a more indolent progression of disease compared with their T790M− counterparts when treated with both first-line TKI and cytotoxic chemotherapy.